Health Technology Assessment Forum

• Print This

The Drug Information Association (DIA) in Europe will host the Health Technology Assessment Forum from November 25-26, 2009 in Paris, France. Health Technology Assessment analyses the short- and long-term consequences of health technology intervention. The escalating progress in medical advances and changes in demographics as well as citizens’ attitudes and demand for services are factors that have put a hard pressure on the health care system. Only a small part of new innovations can be adopted. The need to allocate resources in an efficient way is therefore crucial and obstacles still exist. This two day forum will address:
 
• HTA Methodology and Relevant Data Sources
• European Convergence Process for Regulatory Approvals
• Interfaces of Regulatory—HTA Processes
• Regulatory Benefit Risk Assessment
• Comparing Regulatory and Treatment Guidelines
• Clinical Efficacy versus Clinical Effectiveness
• Regulatory Conditions, Follow-up Measures, Post-approval Studies  and Risk Management Plans
• Drivers for Market Access and Patient Expectations
• Portfolio Management and the Value of Incremental Innovation
• Reimbursement Decisions based on Scientific HTA

Expert speakers will include:
• Hans-Georg Eichler, Senior Medical Officer, EMEA, EU
• Finn B. Kristensen, Project Leader, EUnetHTA, Head of Danish Agency HTA, DACHETA, Denmark
• Georgette Lalis, European Commissions’s Directorate General of Enterprises and Industry, European Commission, EU
• Carole Longson, Director, Centre for Health Technology Evaluation, NICE, UK
• François Meyer, Director, Health Technology Assessment Division, HAS Haute Authorité de Santé, France
• Ad Schuurman, Head of Reimbursement Department, Health Care Insurance Board (CVZ), Chair of the Medicine Evaluation Committee (MEDEV), The Netherlands

Register for the Health Technology Assessment Forum

About the Drug Information Association (DIA)
A non-profit, neutral, multidisciplinary, global, member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of drug development and medical product lifecycle management. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information, visit www.diahome.org or call DIA in Europe on +41 61 225 51 51.